Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 791-798

  Quddusi, Shaista ^a   Vahl, Torsten P ^b   Hanson, Kevin ^b   Prigeon, Ronald L ^a,c   D'Alessio, David A ^a,b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GLUCAGON RELEASE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN INFUSION; INSULIN RELEASE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0043169338     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.791     Document Type: Article

References (38)

1. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 20:876-913, 1999
2. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
3. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
4. D'Alessio DA, Vogel R, Prigeon RL, Laschansky E, Koerker D, Eng J, Ensinck JW: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996
5. Creutzfeldt W: The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109 (Suppl. 2):S288-S303, 2001
6. Drucker DJ: Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399-1412, 2001
7. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307, 1993
8. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by endogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
9. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74, 1994
10. Toft-Nielsen MB, Madsbad S, Holst JJ: Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853-3860, 2001
11. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
12. Nauck MA, Wollschlager D, Wemer J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
13. Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Goke B, Katschinski M: Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 156:177-186, 1998
14. Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR: Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) 95:325-329, 1998
15. Rachman J, Gribble FM, Bartow BA, Levy JE, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
16. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
17. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
18. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
19. Zaharko D, Beck L: Studies of a simplified plasma insulin immunoassay using cellulose powder. Diabetes 17:444-457, 1968
20. Ensinck JW, Shepard C, Dudl R, Williams R: Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasma. J Clin Endocrinol Metab 35:463-468, 1971
21. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
22. Deacon CF, Plamboeck A, Moller S, Holst JJ: GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 282:E873-E879, 2002
23. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
24. Brandt A KM, Arnold R, Polonsky KS, Goke B, Byrne MM: GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol 281:E242-E247, 2001
25. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
26. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide in humans. Diabetes 43:535-539, 1994
27. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
28. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103, 1996
29. Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954-1962, 1967
30. Seltzer HS, Allen EW, Herron AL, Brennan MT: Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46:323-335, 1967
31. Robertson RP: Type II diabetes, glucose "non-sense", and islet desensitization. Diabetes 38:1501-1505, 1989
32. Otonkoski T, Hayek A: Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. J Clin Endocrinol Metab 80:3779-3783, 1995
33. Zawalich WS, Zawalich KC: Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol. Metabolism 45:273-278, 1996
34. Byme MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Goke B: Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 47:1259-1265, 1998
35. Turner RC, McCarthy ST, Holman RR, Harris E: Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1:1252-1254, 1976
36. Vague P, Moulin JP: The defective glucose sensitivity of the B cell in non insulin dependent diabetes: improvement after twenty hours of normoglycaemia. Metabolism 31:139-142, 1982
37. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, Efendic S: Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863, 1996
38. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ: Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24:720-725, 2001